Glial cells and macrophage-derived (especially CD163+ macrophages) CCL2 is an independent prognostic factor in GBM patients, and the CCL2-CCR2/4 axis is a potential GBM immunotherapy target (57). The gene discussed is CCL2; the disease is glioblastoma.